Primary-care doctors who saw PrecivityAD2 blood-test results diagnosed Alzheimer's with 93% accuracy, up from 65%, in findings presented at AAIC 2026. For caregivers, the message is practical: the test helped regular doctors match specialists when a patient already has memory symptoms.
PrecivityAD2 is a blood test that measures Alzheimer's-related proteins in the blood. Researchers led by Lund neurologist Sebastian Palmqvist studied 1,310 Swedish patients with mild impairment or dementia. The work involved 165 primary-care and specialty physicians, according to the Alzheimer's Association in its AAIC 2026 release.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the test measure?
- How much did accuracy improve?
- What does a result mean for your family?
- Can you ask for this test now?
What did the test measure?
PrecivityAD2 measures phosphorylated tau 217 and amyloid-beta ratios, two signals linked to Alzheimer's pathology. Doctors used it alongside clinical evaluation, not alone. Medical Daily, reporting the Lund presentation, describes this combined approach.
In practice, the doctor still takes a history, checks thinking, and rules out other causes. The blood result then adds biological evidence for or against Alzheimer's. That extra signal matters when symptoms are early or unclear.
How much did accuracy improve?
Primary-care accuracy rose from 65% before blood results to 93% after, compared with 94% for dementia specialists, according to Medscape Medical News in its Medscape Medical News report. After disclosure, both groups diagnosed correctly in about 90% of primary-care cases.
The Alzheimer's Association reports wider impact on care decisions. Physicians changed the diagnosis in about one-third of patients. They revised future care, testing, or referral plans in more than half of cases.
What does a result mean for your family?
A result helps sort the next step, not settle every question. The test was especially useful for ruling out Alzheimer's in primary care. A lower-risk result can spare a family months of worry and wrong-direction planning.
A negative result does not exclude other brain causes. The Alzheimer's Association notes that other neurologic problems can still need specialist evaluation. So keep pursuing answers if walking, speech, mood, or daily function keeps worsening.
Can you ask for this test now?
C2N Diagnostics announced FDA clearance of PrecivityAD2 on Aug. 20, 2026 for adults age 40 and older with cognitive symptoms, according to the company in its C2N Diagnostics announcement. It is cleared as an aid with standard workup, not for screening healthy people.
Primary-care use is still catching up to the science. The Alzheimer's Association 2025 blood-biomarker guideline endorses use only in specialty evaluation of symptomatic patients, with primary-care guidance still in development, as stated in the 2025 clinical practice guideline. Bring that symptom timeline to the visit; it helps the doctor decide if testing fits.
- Write down when memory or thinking changes started and what changed
- Bring medicines, sleep, mood, and medical history to the visit
- Ask whether a blood biomarker test fits current clinic policy and workup
- Ask what a positive, negative, or unclear result would change next
You Might Also Like
- The NIA 2026 Dementia Care and Caregiving Summit Report: What the Report Means for Solo Dementia Caregivers
- Early Dementia Detection Across Care Settings in the 2026 NIA Report: A 2026 Follow-Up Checklist for Working Dementia Caregivers
- Care Navigation Research Priorities in the 2026 NIA Report: A 2026 Follow-Up Checklist for Working Dementia Caregivers





